THREE YEARS' EXPERIENCE WITH THE BIOLOGICAL AGENT DENOSUMAB USED TO TREAT WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS: EFFICACY, SAFETY AND TREATMENT ADHERENCE

Objective: to evaluate the efficacy and tolerability of denosumab and adherence to treatment with this drug in women with postmenopausal osteoporosis (OP) during a three-year prospective study under the conditions of routine clinical practice

Subjects and methods. The investigation included 48 women (mean age 65.2±9.1 years) with postmenopausal OP; the patients were recruited in April 2013 to March 2014. All the patients underwent densitometry of three regions and determination of the levels of calcium, creatinine, and alkaline phosphatase over time and vitamin D at inclusion into the study. Adverse events were recorded every 6 months.

Results and discussion. 92% of the patients received denosumab during a year, 81.25 and 66.7% – for two and three years, respectively. In 5 (10.4%) women with a low fracture risk according to the FRAX®, during the treatment their bone mineral density (BMD) reached the level seen with osteopenia or normal levels; and the patients were switched to use only calcium and vitamin D. After 3 years, there were significant BMD increases in the lumbar spine by 8.54%, in the femoral neck by 4.77%, in the entire proximal femur by 5.65%, and in the distal forearm by 1.99%. The prior use of other antiosteoporotic drugs did not reduce the efficiency of denosumab treatment. There was no clinical fractures during a 3-year follow-up. Compliance with dosage regimen was observed in 90.6% of the women who completed the three-year follow-up. Age, marital status, education level, time taken to reach a clinic, parental hip fractures, a history of fractures, duration of OP, and previous treatment did not influence treatment adherence.

Conclusion. The three-year prospective follow-up in real clinical practice has shown that denosumab is an effective and safe agent to treat patients with postmenopausal OP. 

1. Лесняк ОМ, редактор. Остеопороз: Руководство для врачей. Москва: ГЭОТАР-Медиа; 2016. 464 с. [Lesnyak OM, editor. Osteoporoz: Rukovodstvo dlya vrachei [Osteoporosis: A guide for doctors]. Moscow: GEOTAR-Media; 2016. 464 p.].

2. Торопцова НВ, Никитинская ОА. Приверженность лечению остеопороза у больных ревматоидным артритом. Русский медицинский журнал. 2014;(7):491-4 [Toroptsova NV, Nikitinskaya OA. Adherence to the treatment of osteoporosis in patients with rheumatoid arthritis. Russkii Meditsinskii Zhurnal. 2014;(7):491-4 (In Russ.)].

3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-42. doi: 10.1038/nature01658

4. McClung MR, Lewiecki EM, Cohen SB, et al; for the AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-31. doi: 10.1056/NEJMoa044459

5. Miller PD, Bolognese MA, Lewiecki EM, et al; Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43:222-9. doi: 10.1016/j.bone.2008.04.007

6. Cummings SR, San Martin J, McClung MR, et al; for the FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65. doi: 10.1056/NEJMoa0809493

7. McClung MR, Lewiecki EM, Geller ML, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013 Jan;24(1):227-35. doi: 10.1007/s00198-012-2052-4. Epub 2012 Jul 10.

8. Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198- 015-3234-7. Epub 2015 Jul 23.

9. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93:2149-57. doi: 10.1210/jc.2007-2814

10. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24:153-61. doi: 10.1359/jbmr.0809010

11. Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72-81. doi: 10.1359/jbmr.090716

12. Silverman SL, Gold DT. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep. 2008;10:118-22. doi: 10.1007/s11926-008-0021-x

13. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015;26(10):2479-89. doi: 10.1007/s00198-015-3164-4

14. Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int. 2012;23:223-31. doi: 10.1007/s00198-011-1535-z

15. Lakatos P, Toth E, Cina Z, et al. Persistence & compliance to treatment for osteoporosis in postmenopausal women in Hungary: a retrospective cohort study. Value Health. 2013;16:A567-8. doi: 10.1016/j.jval.2013.08.1516

16. Hadji P, Kyvernitakis I, Kann PH, et al. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab. Osteoporos Int. 2016 Oct;27(10):2967-78. doi: 10.1007/s00198- 016-3623-6. Epub 2016 May 12.